Seamless Therapeutics announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company (“Lilly”) to develop and commercialize programmable recombinase-based treatments targeting hearing loss indications, using Seamless’ proprietary recombinase platform. The company’s technology performs large, precise DNA insertions in any target gene sequence, and operates independent of the cell’s natural DNA

Serina Therapeutics, Inc. a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ PlatformTM drug optimization technology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson’s disease. The IND clearance allows Serina to proceed with regulatory and site-level activities to support initiation of a planned

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announced that its anti-GPRC5D/BCMA/CD3 tri-specific antibody IBI3003 has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of relapsed or refractory multiple myelom

iXCells Biotechnologies (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud Biosciences, an innovator in organoid development and complex 3D biology, today announced a partnership to develop a personalized, human-based approach for predicting drug safety and informing translational decision-making in rare diseases. As iXCells enters its next phase of growth, the collaboration expands the Company’s custom integrated platform and

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the first participants have been dosed in a U.S. 13-week Phase II study (NCT07321678) with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026.  Ascletis recently completed a 13-week Phase II study evaluating ASC30 for the treatment of obesity (NCT07002905) in 125 part

World Health Expo (WHX), formerly Arab Health, will bring together the UAE’s health authorities and leading healthcare sector bodies when the exhibition debuts at the Dubai Exhibition Centre (DEC) from 9-12 February 2026. Government entities who have confirmed their participation include the Ministry of Health and Prevention (MoHaP), Dubai Health Authority, the Department of Health Abu Dhabi, and Sharjah Health Authority, as well as Dubai Health, Dubai Healthcare City Authorit

Lexicon Pharmaceuticals, Inc., announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the meeting, the FDA raised no objections to the advancement of pilavapadin into Phase 3 development, which would include two placebo-controlled, 12-week, two arm registrational studies comparing the 10 mg daily dose to placebo. The primary endpoint of the Phase 3 studies

GSK plc today announced that it has entered a definitive agreement to acquire RAPT Therapeutics (“RAPT”) (NASDAQ: RAPT), a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases. The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in phase IIb clinical development for prophylactic protection against food allergens. &

Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), announced a strategic collaboration to advance U.S. verification and clinical validation of liquid biopsy assays designed for cancer detection, profiling, and monitoring. Under the agreement, Gene Solutions will provide SOPs, funding, and technical support from its CAP-accredited

Transforming healthcare systems and hospitals for a smarter, sustainable and human-centric future. In an era defined by digital transformation and healthcare disruption, Healthcare & Hospi.Log 2026 will bring together global hospital leaders, health ministries, insurers, innovators, and technology partners to explore how hospitals can evolve into intelligent, integrated, and resilient ecosystems and the next frontier of healthcare transformation. The conference focuses on the co